Thoracic Cancer最新文献_第4页

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC. adagrasib治疗的NSCLC多克隆KRAS耐药的ctDNA检测。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70313

Marion Caumeil, Julie A Vendrell, Simon Cabello-Aguilar, Sarah Cavaillon, Quentin Dominique Thomas, Jérôme Solassol

{"title":"ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.","authors":"Marion Caumeil, Julie A Vendrell, Simon Cabello-Aguilar, Sarah Cavaillon, Quentin Dominique Thomas, Jérôme Solassol","doi":"10.1111/1759-7714.70313","DOIUrl":"10.1111/1759-7714.70313","url":null,"abstract":"Circulating tumor DNA (ctDNA) monitoring may detect resistance to KRASG12C inhibitors earlier than conventional imaging. However, in the specific context of KRASG12C inhibitors, the temporal relationship between molecular, radiologic, and clinical progression remains poorly characterized. A 66-year-old woman with KRASG12C/STK11/KEAP1-mutant lung adenocarcinoma received second-line adagrasib after progression on chemo-immunotherapy. Serial ctDNA monitoring by droplet digital PCR and targeted next-generation sequencing was performed. Baseline KRASG12C ctDNA (6205.3 copies/mL) declined to 3.2 copies/mL after 7 weeks, indicating initial response. However, ctDNA levels rose to 21.1 copies/mL at month 4 and 315.2 copies/mL at month 6. Concurrent NGS revealed three emergent KRAS mutations (G12D, G13D, Q61H), confirming polyclonal resistance. Notably, CT and MRI imaging remained stable by RECIST criteria throughout this period. Significant clinical deterioration, requiring prolonged hospitalization, occurred approximately 8 weeks after initial ctDNA rise. The patient died 2 months after detection of resistance mutations. In this case, NGS ctDNA detected three acquired KRAS resistance mutations in addition to the original G12C, during a prolonged period of radiographic stability, illustrating polyclonal evolution under adagrasib pressure. These findings suggest that longitudinal liquid biopsy monitoring may provide early detection of resistance in KRASG12C-mutant NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 15","pages":"e70313"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13420328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148621491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exceptional Response of HER2-Positive Breast Cancer to Osimertinib: A Case Report. her2阳性乳腺癌对奥西替尼的特殊反应：一例报告。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70379

Hirotoshi Yasui, Misaki Hatasa, Ko Ohara, Kaito Sano, Yasutaka Mori, Tomofumi Shibata, Yasutaka Fukui, Mitsuru Odate, Yoshifumi Arai, Masahiro Fujii, Yasushi Makino

引用次数: 0

Clamshell and Hemiclamshell Incisions for Complex Intrathoracic Tumors: A Retrospective Analysis of Indications and Outcomes. 翻盖和半翻盖切口治疗复杂胸内肿瘤：适应症和结果的回顾性分析。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70373

Marco Mammana, Vincenzo Verzeletti, Giulia Pagliarini, Alessandro Bonis, Viola Sambataro, Federico Rea, Andrea Dell'Amore

{"title":"Clamshell and Hemiclamshell Incisions for Complex Intrathoracic Tumors: A Retrospective Analysis of Indications and Outcomes.","authors":"Marco Mammana, Vincenzo Verzeletti, Giulia Pagliarini, Alessandro Bonis, Viola Sambataro, Federico Rea, Andrea Dell'Amore","doi":"10.1111/1759-7714.70373","DOIUrl":"https://doi.org/10.1111/1759-7714.70373","url":null,"abstract":"Introduction: Clamshell and hemiclamshell incisions are uncommon approaches in thoracic oncology. This study aims to describe indications and outcomes of surgical resection using these two incisions and to propose criteria that may prompt their use.Methods: We retrospectively reviewed patients undergoing tumor resection via clamshell or hemiclamshell incision between 2009 and 2024. Patient characteristics and outcomes were descriptively analyzed.Results: Clamshell and hemiclamshell approaches were used in 36 and 55 cases, respectively. Median tumor diameter was 10 cm (IQR: 6.4-14.0). Pneumonectomy, vascular resections, and tracheo/bronchoplastic procedures were performed in 41.4%, 33%, and 12.1% of cases; extracorporeal support was required in 11%. Distinct patterns of tumor histology and intrathoracic location were observed between the two approaches. Pneumonectomy and tracheo-carinal resections were mainly performed through clamshell, while pleural resections were predominantly carried out through hemiclamshell (p < 0.05). Postoperative hospital stay was longer in the clamshell group (13 vs. 11 days), whereas other early outcomes were comparable. Overall survival and cause-specific mortality were similar.Conclusion: This study provides a descriptive analysis of the clinical use of clamshell and hemiclamshell incisions in thoracic oncology. Distinct indications emerged for each approach, reflecting tumor location and extent. Both techniques were associated with acceptable perioperative outcomes, while long-term results appeared to be mainly influenced by tumor characteristics. The proposed illustrative algorithm may aid in selecting surgical access for complex intrathoracic tumors.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70373"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13483318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RETRACTION: The Kinesin Light Chain-2, a Target of mRNA Stabilizing Protein HuR, Inhibits p53 Protein Phosphorylation to Promote Radioresistance in NSCLC. 摘要：作为mRNA稳定蛋白HuR靶点的激酶蛋白轻链-2抑制p53蛋白磷酸化促进非小细胞肺癌的放射耐药。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70380

引用次数: 0

Diabetes Mellitus as an Independent Risk Factor for Unfavorable Prognosis in Patients With Small Cell Lung Cancer. 糖尿病是小细胞肺癌患者预后不良的独立危险因素。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70378

Rui Yan, Patiguli Yisilamu, Yang Ge, Weiwei Zhou

{"title":"Diabetes Mellitus as an Independent Risk Factor for Unfavorable Prognosis in Patients With Small Cell Lung Cancer.","authors":"Rui Yan, Patiguli Yisilamu, Yang Ge, Weiwei Zhou","doi":"10.1111/1759-7714.70378","DOIUrl":"10.1111/1759-7714.70378","url":null,"abstract":"Background: Type 2 diabetes mellitus (DM) is implicated in cancer development and associated with poor survival in patients with cancer. However, the impact of DM on the outcome of small cell lung cancer (SCLC) remains unknown. This study investigated the correlation between DM and clinical outcomes and long-term prognosis of patients with extensive-stage small cell lung cancer (ES-SCLC).Methods: This retrospective cohort study was conducted using the medical records of patients with ES-SCLC treated with immune checkpoint inhibitors (ICIs) and chemotherapy. The demographic and clinical characteristics were retrospectively analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards regression to evaluate the impact of the clinical characteristics on survival. Progression-free survival (PFS) and overall survival (OS) were compared between patients with or without DM.Results: Of the 91 patients with ES-SCLC, 32 were diagnosed with DM before ES-SCLC (35.2%). Patients with DM had significantly shorter median PFS (6 vs. 15 months, p = 0.026) and median OS (12 vs. 22 months, p = 0.013) than those without diabetes, despite receiving comparable chemoimmunotherapy. Multivariate cox regression analysis showed that DM was an independent risk factor for shorter mOS (HR 2.05, 95% CI 1.02-4.13, p = 0.044).Conclusions: Patients with ES-SCLC and comorbid diabetes exhibited significantly shorter OS and PFS compared with those without diabetes. DM serves as an independent adverse prognostic risk factor for ES-SCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70378"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148723903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018-2022: A Nationwide Analysis in Japan. 2018-2022年晚期胸腺瘤和晚期胸腺癌治疗实践：日本全国范围内的分析

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70367

Junichi Ishigaki, Ryoko Rikitake, Hidenori Kage, Takahiro Higashi

{"title":"Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018-2022: A Nationwide Analysis in Japan.","authors":"Junichi Ishigaki, Ryoko Rikitake, Hidenori Kage, Takahiro Higashi","doi":"10.1111/1759-7714.70367","DOIUrl":"10.1111/1759-7714.70367","url":null,"abstract":"Introduction: Thymomas and thymic carcinomas are rare diseases with limited clinical evidence. This study aimed to investigate the clinical characteristics of and treatment practices for Stages III and IV thymoma or thymic carcinoma in Japan.Methods: We analyzed cases of Stage III and IV thymoma and thymic carcinoma diagnosed between 2018 and 2022 and recorded in a nationwide dataset linking the Hospital-based Cancer Registry and the Diagnosis Procedure Combination survey. Treatment practices, including the use of perioperative chemotherapy, radiotherapy, and newer systemic therapies as well as the chemotherapy regimens, were evaluated.Results: Overall, 556 stage III thymoma, 312 stage III thymic carcinoma, 431 stage IV thymoma, and 976 stage IV thymic carcinoma patients were identified. Postoperative radiotherapy after complete resection was more common for stage III thymic carcinoma than for thymoma (34.1% vs. 10.7%), while perioperative chemotherapy was used more frequently for stage IV thymoma than for thymic carcinoma (preoperative: 15.5% vs. 3.7%; postoperative: 8.4% vs. 4.4%). For stage IV thymoma, adriamycin-cisplatin-vincristine-cyclophosphamide was the most common regimen (41.8%), whereas carboplatin-paclitaxel was predominantly used for stage IV thymic carcinoma (99.5%). The proportion of anthracycline-based therapy for stage IV thymoma increased from 50.0% to 77.8%, while that of postoperative radiotherapy for stage III thymoma decreased from 11.1% to 4.1%.Conclusions: Evidence-based treatment approaches for thymoma and thymic carcinoma have been widely adopted in Japan.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 15","pages":"e70367"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cigarette Smoke Extract Promotes Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer by Upregulating PRMT6. 香烟烟雾提取物通过上调PRMT6促进非小细胞肺癌上皮-间质转化。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70357

Yanwen Zhang, Xiaojing Chang, Jie Cao, Jing Zhang, Haiyan Zhao

{"title":"Cigarette Smoke Extract Promotes Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer by Upregulating PRMT6.","authors":"Yanwen Zhang, Xiaojing Chang, Jie Cao, Jing Zhang, Haiyan Zhao","doi":"10.1111/1759-7714.70357","DOIUrl":"10.1111/1759-7714.70357","url":null,"abstract":"Background and objective: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Cigarette smoke extract (CSE) is a major environmental factor driving NSCLC progression, yet the underlying molecular mechanisms remain incompletely understood. Protein arginine methyltransferase 6 (PRMT6) is implicated in various malignancies, including NSCLC, and epithelial-mesenchymal transition (EMT) contributes to metastasis and poor prognosis in this disease. However, the role of PRMT6 in CSE-induced NSCLC progression has not been elucidated.Methods: NSCLC progression under CSE exposure was assessed using a subcutaneous xenograft model in nude mice and in vitro assays in H1299 cells. Tumor growth and molecular alterations were evaluated by immunohistochemistry, CCK-8, wound healing, Transwell, immunofluorescence, qRT-PCR, and western blotting.Results: CSE exposure enhanced H1299 cell proliferation, migration, and invasion in vitro and promoted xenograft tumor growth in vivo. This was accompanied by upregulated expression of PRMT6 and its effector H3R2me2a, elevated mesenchymal markers (N-cadherin, MMP2, MMP9, vimentin), and transcription factors (Snail, TWIST1), and increased phosphorylation of PI3K p85, Akt, and mTOR. Notably, all CSE-induced effects were abrogated by the PRMT6 inhibitor EPZ020411.Conclusion: CSE promotes NSCLC progression by upregulating PRMT6, leading to PI3K/Akt/mTOR activation and EMT induction. These findings highlight PRMT6 as a potential therapeutic target in NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70357"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148723658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors. 重新定义化疗和靶向细胞毒在肺神经内分泌肿瘤中的作用。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-08-01 DOI: 10.1111/1759-7714.70376

Alice Laffi, Giuseppe Lamberti, Anna La Salvia

{"title":"Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors.","authors":"Alice Laffi, Giuseppe Lamberti, Anna La Salvia","doi":"10.1111/1759-7714.70376","DOIUrl":"10.1111/1759-7714.70376","url":null,"abstract":"The clinicopathological and therapeutic landscape of lung neuroendocrine tumors (NETs) is continuously evolving. Although systemic chemotherapy has historically represented a management cornerstone, the available data are predominantly retrospective and outdated. A critical review of the current literature and public clinical trial registries was performed to evaluate the role of chemotherapy and targeted cytotoxic delivery systems in lung NETs. Given the nature of the review, the evidence was synthesized descriptively. In early-stage disease, the clinical utility of perioperative (neoadjuvant and adjuvant) chemotherapy remains uncertain and lacks universal standardization. In the advanced or metastatic setting, traditional platinum/etoposide regimens demonstrate suboptimal efficacy in controlling well-differentiated carcinoids. Conversely, oral alkylating agents (temozolomide) and combination schedules such as CAPTEM (capecitabine/temozolomide) or temozolomide paired with cabozantinib offer promising response and disease control rates. Future strategies are moving away from unselected systemic cytotoxicity toward targeted delivery and chemo-immunotherapy platforms, leveraging peptide-drug conjugates (PDCs like PEN-221), antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs) directed against emerging surface targets such as DLL3 (e.g., tarlatamab) and TROP2. There is an urgent, unmet clinical need for prospective, multicenter clinical trials and international registries. Dissecting the complex molecular landscape of lung NETs will be essential to identify predictive biomarkers and actionable therapeutic targets, ultimately transitioning clinical management from empirical, extrapolated choices to robust, evidence-based, stage-specific standards of care.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 16","pages":"e70376"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin 32 Expression in Mesothelioma. 白介素32在间皮瘤中的表达。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-07-01 DOI: 10.1111/1759-7714.70353

Takuya Mikamo, Riko Niwa, Yuki Hanamatsu, Tamotsu Takeuchi

{"title":"Interleukin 32 Expression in Mesothelioma.","authors":"Takuya Mikamo, Riko Niwa, Yuki Hanamatsu, Tamotsu Takeuchi","doi":"10.1111/1759-7714.70353","DOIUrl":"10.1111/1759-7714.70353","url":null,"abstract":"Background: Interleukin 32 (IL32) has context-dependent roles in carcinogenesis across cancer types. In this study, we examined IL32 in mesotheliomas.Methods: IL32 protein expression was evaluated by immunohistochemistry in 56 mesothelioma tissue microarray specimens and by immunoblot analysis in cultured mesothelioma cell lines. The functional roles of IL32 were examined through ectopic expression of IL32β and IL32θ isoforms in D-Meso-Sonobe cells with epithelial-mesenchymal plasticity and through siRNA-mediated IL32 downregulation followed by cell-detachment-induced apoptosis assays in epithelioid mesothelioma cells.Results: IL32 immunoreactivity was detected in 20 of 56 mesothelioma tissue specimens, including cytoplasmic staining in 20 of 39 epithelioid cases, whereas little or no immunoreactivity was found in 17 sarcomatoid cases. In immunoblot analysis, an IL32 protein band was detected in two cultured epithelioid mesothelioma cell lines (MPM-2 and TCC-Meso-1), but not in sarcomatoid MPM-1 cells. Two IL32 isoforms, IL32β and IL32θ cDNAs, were isolated from MPM-2 cells. Ectopic expression of IL32θ, but not IL32β, inhibited the morphological transition from epithelioid to sarcomatoid features in D-Meso-Sonobe mesothelioma cells with mesothelial-mesenchymal transition plasticity. Conversely, siRNA-mediated downregulation of IL32 increased cell detachment-induced apoptosis in MPM-2 and TCC-Meso-1 epithelioid mesothelioma cells. Moreover, IL32 suppressed expression of secreted protein acidic and rich in cysteine, which is an epithelial-mesenchymal transition-related protein in mesothelioma cells.Conclusions: These findings indicate that IL32 is expressed in epithelioid mesothelioma and may contribute to mesotheliomagenesis.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"17 14","pages":"e70353"},"PeriodicalIF":2.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13370107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endobronchial Metastasis From Osteosarcoma in an Adolescent: A Rare Case Report. 青少年骨肉瘤支气管内转移一例罕见病例报告。

IF 2.6 3区医学

Thoracic Cancer Pub Date : 2026-07-01 DOI: 10.1111/1759-7714.70355

Yanling He, Yanping Chen, Yanhong Liu, Juyan Chen, Ahmad Muhammad, Huiwen Jin, Yi Xiao

引用次数: 0